一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Cell Death & Disease >>article
Cell Death & Disease

Cell Death & Disease

IF: 8.1
Download PDF

Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins.

Published:2 November 2023 DOI: 10.1038/s41419-023-06233-w PMID: 37919300
Yijing Li, Heng-Huan Lee, Vivian Changying Jiang, Yuxuan Che, Joseph McIntosh, Alexa Jordan, Jovanny Vargas, Tianci Zhang, Fangfang Yan, Margaret Elizabeth Simmons, Wei Wang, Lei Nie, Yixin Yao, Preetesh Jain, Michael Wang, Yang Liu

Abstract

Bruton's tyrosine kinase inhibitors (BTKi) and CAR T-cell therapy have demonstrated tremendous clinical benefits in mantle cell lymphoma (MCL) patients, but intrinsic or acquired resistance inevitably develops. In this study, we assessed the efficacy of the highly potent and selective MCL-1 inhibitor AZD5991 in various therapy-resistant MCL cell models. AZD5991 markedly induced apoptosis in these cells. In addition to liberating BAK from the antiapoptotic MCL-1/BAK complex for the subsequent apoptosis cascade, AZD5991 downregulated inhibitor of apoptosis proteins (IAPs) through a BAK-dependent mechanism to amplify the apoptotic signal. The combination of AZD5991 with venetoclax enhanced apoptosis and reduced mitochondrial oxygen consumption capacity in MCL cell lines irrespective of their BTKi or venetoclax sensitivity. This combination also dramatically inhibited tumor growth and prolonged mouse survival in two aggressive MCL patient-derived xenograft models. Mechanistically, the augmented cell lethality was accompanied by the synergistic suppression of IAPs. Supporting this notion, the IAP antagonist BV6 induced dramatic apoptosis in resistant MCL cells and sensitized the resistant MCL cells to venetoclax. Our study uncovered another unique route for MCL-1 inhibitor to trigger apoptosis, implying that the pro-apoptotic combination of IAP antagonists and apoptosis inducers could be further exploited for MCL patients with multiple therapeutic resistance.

Substances (14)

Materials Related products
Procduct Name CAS Molecular Formula Supplier Price
BV6 1001600-56-1 C70H96N10O8 112 suppliers $22.00-$2841.00
BV6 1001600-56-1 C70H96N10O8 112 suppliers $22.00-$2841.00
BV6 1001600-56-1 C70H96N10O8 112 suppliers $22.00-$2841.00
BV6 1001600-56-1 C70H96N10O8 112 suppliers $22.00-$2841.00
S63845 1799633-27-4 C39H37ClF4N6O6S 108 suppliers $56.00-$6500.00
S63845 1799633-27-4 C39H37ClF4N6O6S 108 suppliers $56.00-$6500.00
S63845 1799633-27-4 C39H37ClF4N6O6S 108 suppliers $56.00-$6500.00
S63845 1799633-27-4 C39H37ClF4N6O6S 108 suppliers $56.00-$6500.00
MIK665 1799631-75-6 C47H44ClFN6O6S 80 suppliers Inquiry
MIK665 1799631-75-6 C47H44ClFN6O6S 80 suppliers Inquiry

Similar articles

IF:4.6

Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor.

Clinical Pharmacokinetics Neeraj Gupta, Michael J Hanley,etc Published: 1 August 2023
阜南县| 唐海县| 高雄县| 永胜县| 大余县| 大同市| 乌苏市| 于田县| 东乡县| 尖扎县| 柞水县| 化州市| 两当县| 自贡市| 延川县| 承德市| 新巴尔虎右旗| 崇左市| 阿瓦提县| 肥西县| 泰宁县| 安乡县| 鹤峰县| 潍坊市| 澄江县| 合作市| 兴山县| 定南县| 河源市| 兰西县| 临西县| 隆昌县| 郎溪县| 宝清县| 台中市| 萨迦县| 东山县| 栾城县| 丰顺县| 康保县| 驻马店市|